MARKET WIRE NEWS

MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors

MWN-AI** Summary

MEDIROM MOTHER Labs Inc., a subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), has successfully completed a private placement of new shares to its President and CEO, Yoshio Uekusa, and Director, Ryo Saito, as part of its Series A funding round, valued at ¥9 billion. This strategic move aims to bolster the company's operational capacity and facilitate swift decision-making through direct investment from its management team.

The company focuses on the health tech sector and is known for its healthcare app “Lav” and the innovative wearable device “MOTHER Bracelet.” By enhancing its management’s investment stake, MEDIROM MOTHER Labs seeks to increase business accountability and motivation for growth. The funds raised will strengthen the company’s capital base, enabling it to accelerate the development of upgraded versions of the MOTHER Bracelet and streamline processes for launching new products into the market.

MEDIROM MOTHER Labs emphasizes its commitment to providing tailored health management solutions, leveraging the unique features of the recharge-free MOTHER Bracelet. The company's initiatives span various sectors, including caregiving, logistics, and manufacturing, demonstrating its versatility in addressing diverse health needs.

Looking ahead, MEDIROM MOTHER Labs is poised to drive sustainable growth both in Japan and internationally, aiming to deliver new value in the healthcare and wellness industry. This investment marks a significant step as the company seeks to establish itself as a leader in digital preventative healthcare while navigating challenges posed by market dynamics and evolving consumer preferences.

The announcement underscores MEDIROM's ambition to expand its impact within the health tech landscape while maintaining a focus on responsible governance and innovation.

MWN-AI** Analysis

MEDIROM MOTHER Labs Inc., a burgeoning player in the health-tech sector, has recently completed a private placement of new shares, raising ¥9 billion in a Series A funding round. This investment from the company’s top executives, including President and CEO Yoshio Uekusa, signals a robust commitment to enhancing the company's growth trajectory.

The infusion of capital is particularly crucial as MEDIROM aims to bolster its product development, specifically the upgraded versions of the “MOTHER Bracelet.” This wearable technology aligns with the emerging trends in health management, offering customizable solutions across various industries including caregiving and logistics. MEDIROM's strategic focus on integrating healthcare technology and smart tracking can position it well within a competitive landscape increasingly dominated by digital health innovations.

Investors should be mindful of the following when considering MEDIROM MOTHER Labs: First, the company’s management investing their own capital is a strong indicator of confidence in future growth and business responsibility. This alignment of interests could foster a culture of accountability that may positively influence operational execution.

Secondly, MEDIROM’s dual strategy—enhancing its existing offerings while expanding its market presence—demonstrates its agility within a rapidly evolving market. However, potential investors should take note of the inherent risks outlined in the forward-looking statements, including fluctuations in economic conditions and consumer preferences that could impact profitability and growth prospects.

In summary, MEDIROM MOTHER Labs presents an attractive opportunity for strategic investors looking for exposure in the health-tech space. The recent leadership investment and strategic initiatives indicate potential for long-term growth, though investors should remain cognizant of market challenges that may affect performance. As always, diversifying investments and conducting due diligence are recommended before making investment decisions.

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Source: GlobeNewswire

TOKYO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Co., Ltd. (Headquarters: Minato-ku, Tokyo; President and CEO: Yoshio Uekusa; hereinafter “MEDIROM MOTHER Labs”), a subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), has completed a private placement of new shares to its President and CEO, Yoshio Uekusa, and Director, Ryo Saito. This transaction is part of the previously announced Series A round, valued at ¥9 billion.

?Background of Implementation
MEDIROM MOTHER Labs, as the health tech division of the Medirom Group, has been advancing the implementation of specific health guidance utilizing the healthcare app “Lav” and the development and sales of the wearable device “MOTHER Bracelet”. To further expand our business going forward, we aim to enhance swift decision-making and a field-driven management structure. By having the management team itself become investors, we seek to further increase business responsibility and growth motivation.

?Future Outlook
With the completion of this capital increase, MEDIROM MOTHER Labs will further strengthen its capital base and accelerate the development of upgraded versions of the wearable device “MOTHER Bracelet” and the establishment of systems for launching new products into the market. As the Medirom Group, we will realize the delivery of new value in the healthcare and wellness field and drive sustainable growth both domestically and internationally.

ABOUT MEDIROM MOTHER Labs Inc.


A subsidiary of MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), focuses on the health- tech sector. The company’s core activities include the 'Specific Health Guidance Program' offered through the 'Lav' health application and development and sales of the 24/7 recharge-free MOTHER Bracelet smart tracker. By leveraging the features of the recharge-free MOTHER Bracelet, MOTHER Labs offers customizable health management solutions across diverse sectors, including caregiving, logistics, manufacturing, etc.

?MEDIROM Healthcare Technologies Inc.


MEDIROM Healthcare Technologies Inc.
NASDAQ Symbol: MRM
Tradepia Odaiba, 2-3-1 Daiba, Minato-ku, Tokyo, Japan
Web: https://medirom.co.jp/en
Contact: ir@medirom.co.jp

Forward-Looking Statements Regarding MEDIROM
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity. Some of the factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release include:

  • MEDIROM’s ability to achieve its development goals for its business and execute and evolve its growth strategies, priorities and initiatives;

  • changes in Japanese and global economic conditions and financial markets, including their effects on MEDIROM’s expansion in Japan and certain overseas markets;

  • MEDIROM’s ability to achieve and sustain profitability in its Digital Preventative Healthcare Segment;

  • the fluctuation of foreign exchange rates, which affects MEDIROM’s expenses and liabilities payable in foreign currencies;

  • MEDIROM’s ability to maintain and enhance the value of its brands and to enforce and maintain its trademarks and protect its other intellectual property;

  • MEDIROM’s ability to raise additional capital on acceptable terms or at all;

  • MEDIROM’s level of indebtedness and potential restrictions on MEDIROM under MEDIROM’s debt instruments;

  • changes in consumer preferences and MEDIROM’s competitive environment;

  • MEDIROM’s ability to respond to natural disasters, such as earthquakes and tsunamis, and to global pandemics, such as COVID-19; and

  • the regulatory environment in which MEDIROM operates.

More information on these risks and other potential factors that could affect MEDIROM’s business, reputation, results of operations, financial condition, and stock price is included in MEDIROM’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of MEDIROM’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/88366bf6-f544-42a6-883a-44e4a00ce143

https://www.globenewswire.com/NewsRoom/AttachmentNg/6f209e52-40b4-4ad3-838c-146ee389b046


FAQ**

How does MEDIROM Healthcare Technologies Inc. (MRM) plan to utilize the ¥9 billion raised in the recent private placement to support its growth strategy and product developments?

MEDIROM Healthcare Technologies Inc. (MRM) plans to utilize the ¥9 billion raised in the recent private placement to enhance growth by investing in product development, expanding its healthcare services, and advancing technology initiatives to better serve its customers.

As a subsidiary, how does MEDIROM MOTHER Labs intend to leverage its relationship with MEDIROM Healthcare Technologies Inc. (MRM) to enhance its market presence in the health tech sector?

MEDIROM MOTHER Labs aims to leverage its relationship with MEDIROM Healthcare Technologies Inc. by integrating innovative health solutions, utilizing shared resources and expertise, and enhancing collaborative marketing efforts to strengthen its market presence in the health tech sector.

What specific features or advancements can investors expect in the upcoming upgraded versions of the MOTHER Bracelet as part of MEDIROM Healthcare Technologies Inc. (MRM)'s strategic objectives?

Investors can expect enhanced health monitoring capabilities, improved user interface, integration with advanced AI analytics, and expanded compatibility with wellness applications in the upcoming upgraded versions of the MOTHER Bracelet from MEDIROM Healthcare Technologies Inc. (MRM).

Given the competitive landscape, what measures is MEDIROM MOTHER Labs taking to differentiate itself in the health tech market while aligning with the broader goals of MEDIROM Healthcare Technologies Inc. (MRM)?

MEDIROM MOTHER Labs is differentiating itself in the health tech market by focusing on innovative wellness solutions, leveraging advanced technology for personalized healthcare, and aligning its strategic initiatives with MEDIROM Healthcare Technologies Inc.'s overarching mission of enhancing overall health management.

**MWN-AI FAQ is based on asking OpenAI questions about MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM).

MEDIROM Healthcare Technologies Inc.

NASDAQ: MRM

MRM Trading

-0.67% G/L:

$1.2515 Last:

15,256 Volume:

$1.23 Open:

mwn-ir Ad 300

MRM Latest News

MRM Stock Data

$10,280,437
6,020,496
N/A
3
N/A
Personal Services
Consumer Discretionary
JP
Tokyo

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App